Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

316
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
316
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

340
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
340
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

298
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
298
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

308
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
308
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.4K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

305
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

International journal of geriatric psychiatry·2000
Same author

The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample.

Archives of neurology·2000
Same author

Expression of interleukin 1 alpha and beta, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides.

Cytokine·2000
Same author

Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project.

Neurology·2000
Same author

Mild cognitive impairment in the population and physical health: data on 1,435 individuals aged 75 to 95.

The journals of gerontology. Series A, Biological sciences and medical sciences·2000
Same author

Influencing aspects in nursing education on Swedish nursing students' choices of first work area as graduated nurses.

The Journal of nursing education·2000

Related Experiment Video

Updated: Mar 15, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.9K

Inverse relationship between erythrocyte size and platelet reactivity in elderly.

M Milovanovic1,2, S Nilsson3, B Winblad4,5

  • 1a Department of Internal Medicine, Vrinnevi Hospital , Norrköping , Sweden.

Platelets
|August 26, 2016
PubMed
Summary

Increased red blood cell (RBC) volume (MCV) in older adults correlates with reduced platelet reactivity, mirroring changes seen in Alzheimer's disease (AD). This suggests a link between RBC health and blood clotting function in aging populations.

Keywords:
Alzheimer´s diseaseelderlyerythrocytesfibrinogenmean corpuscular volumeplatelet activityplatelet densityplatelet reactivityβ-amyloid

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.9K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.3K

Area of Science:

  • Gerontology and Aging Research
  • Hematology
  • Neurodegenerative Diseases

Background:

  • Erythrocytes (RBCs) accumulate β-amyloid-40 (Aβ40) in Alzheimer's disease (AD), potentially affecting RBC function and volume.
  • Platelet reactivity is reduced in individuals with AD.
  • The interplay between RBCs and platelets in aging individuals, particularly those with hypertension, requires further investigation.

Purpose of the Study:

  • To investigate the relationship between RBCs and platelets in older adults with moderate hypertension.
  • To examine the association between mean corpuscular volume (MCV) and platelet reactivity.
  • To explore the potential resemblance of observed RBC and platelet behaviors to those in AD.

Main Methods:

  • Participants (n=57) with hypertension were divided into high MCV and low MCV groups.
  • Platelet reactivity was assessed using flow cytometry measuring fibrinogen binding after stimulation with ADP and TRAP-6.
  • Intra-erythrocyte Aβ40 content was analyzed, and blood cells were fractionated by density.

Main Results:

  • Aβ40 was found within RBCs of approximately 50% of participants, but did not impact MCV or platelet reactivity.
  • Higher MCV was inversely associated with platelet reactivity, indicated by reduced surface-bound fibrinogen after agonist stimulation (p < 0.05).
  • This inverse relationship between MCV and platelet activity was observed across various blood cell density fractions.

Conclusions:

  • In community-dwelling older adults with hypertension, increased MCV is linked to decreased platelet reactivity and lower in vivo platelet activity.
  • The findings suggest that altered RBC characteristics, specifically higher MCV, may impair platelet function.
  • The observed RBC and platelet behavior patterns in this cohort resemble those seen in AD-type dementia.